ABSTRACT
Objective:To investigate the clinical significance of protein disulfide isomerase A3 (PDI) A3 (PDIA3) expression in hepatocellular carcinoma tissues and its effect of PDIA3 on the expression of IL6 and IL17 in hepatocellular carcinoma cells.Methods:Immunohistochemistry was used to detect the expression of PDIA3 in the tissues of 72 patients with liver cancer and their adjacent tissues. HepG2 cells were divided into experimental group and control group. The cells in the experimental group were transfected with PDIA3-siRNA plasmid, and the cells in the control group were transfected with MOCK-siRNA plasmid. Fluorescence quantitative PCR was used to detect the content of PDIA3 mRNA in each group of cells. The expressions of PDIA3, IL6 and IL17 in each group of cells were detected by Western blot. The proliferation ability of each group of cells was detected by CCK8.Results:The positive rate of PDIA3 in liver cancer tissues was 85.22% (75/88), and the expression rate in adjacent tissues was 6.81% (6/88). The expression rate of PDIA3 in liver cancer tissues was significantly higher than that in adjacent tissues. The difference was statistically significant ( P<0.001). After transfection of siRNA, the expression levels of PDIA3 mRNA in HepG2 cells in the experimental group and control group were 1.23±0.20 and 0.43±0.12, respectively, and the expression levels of PDIA3 protein were 1.19±0.11 and 0.23±0.08, respectively. The expression levels of IL6 were 1.11±0.15 and 0.57±0.09, respectively. The expression levels of IL17 were 1.19±0.14 and 0.45±0.08, respectively, and the expressions of IL6 and IL17 were significantly decreased (all P<0.05). The absorbance of HepG2 cells in the experimental group and the control group at 120 h was 2.28±0.10 and 1.11±0.09, respectively, and the cell proliferation ability of the experimental group was significantly decreased ( P<0.05) . Conclusions:The expression of PDIA3 is significantly increased in hepatocellular carcinoma, which may be related to the malignancy of hepatocellular carcinoma. PDIA3 affects the proliferation of hepatocellular carcinoma cells by regulating the expression of IL6 and IL17.
ABSTRACT
Objective To evaluate the expression of the total serum IgG and IgG subclasses of anti-PDIA3 antibody (PDIA3 Ab) in patients with autoimmune thyroiditis (AIT) and discuss its association with thyroid peroxidase antibody (TPOAb), thyroglobulin antibody (TgAb), and thyroid function. Methods The PDIA3 Ab total serum IgG and IgG subtype levels were detected by ELISA and thyrotrophin (TSH), free triiodothyronine (FT3), free thyroxine (FT4), TPOAb, and TgAb serum levels were detected by electrochemiluminescence immunoassays. Results Levels of PDIA3 Ab total serum IgG, IgG1, and IgG3 in patients in the AIT group were significantly higher than those in the non-AIT group (P ＜ 0.05). There were no significant differences in PDIA3 Ab total IgG and IgG subtype levels in the AIT with euthyroidism group and hypothyroidism group (P＞ 0.05). In the AIT with hypothyroidism group, PDIA3 Ab IgG1 subtype serum level was negatively correlated with that of TgAb (r =-0.679, P ＜ 0.05), and positively correlated with that of TSH while controlling the variables of TPOAb and TgAb (r = 0.550, P ＜ 0.05). No significant correlation was found among PDIA3 Ab total IgG and IgG3 subclass, TPOAb, TgAb, TSH, FT3, and FT4 in AIT (P＞ 0.05). Conclusion Apart from thyroid peroxidase and thyroglobulin, PDIA3 may be a non-classical autoantigen of AIT and may play an important role in thyroid-related injury.
ABSTRACT
Protein disulfide isomerase A3 (PDIA3) is a member of protein disulphide isomerase family and widely exists in endoplasmic reticulum, cell surface, nucleus and mitochondria.PDIA3 promotes the glycoprotein folding and quality control in the endoplasmic reticulum and is also a key molecular of major histocompatibility complex class I mol-ecules assembly.In addition, PDIA3 is involved in the cell signal transduction and plays an important role in a variety of disease development.Therefore, this paper talks about the function of PDIA3, the relationship between disease and PDIA3 as well as its clinical outlook.